Literature DB >> 18805673

Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use.

Miguel Ruiz-Veguilla1, Manuel Gurpegui, María Luisa Barrigón, Maite Ferrín, Esther Marín, José Luis Rubio, Blanca Gutiérrez, Antonio Pintor, Jorge Cervilla.   

Abstract

BACKGROUND: Although neurological soft signs (NSS) have been consistently associated with schizophrenia and a variety of risk factors, few studies have focused on the association between NSS and environmental factors such as cannabis use, particularly in patients with first episode psychosis.
METHODS: We administered the Neurological Evaluation Scale (NES) to 92 patients during their first episode of functional psychosis. Psychopathology was assessed with the Positive And Negative Syndrome Scale (PANSS) and the family history of psychotic disorder was established on the basis of the Family Interview for Genetic Studies (FIGS). We also assessed lifetime cannabis and cocaine use utilizing that specific section of the Composite International Diagnostic Interview. The outcome variable was the presence of high NSS, defined by a score above the median split of the NES score (>21).
RESULTS: Most patients (80/92, 87%) presented a non-affective psychosis. The presence of high NSS showed a significant independent association with not having been a heavy cannabis user (OR=8.3; 95% CI, 2.4-33.3), family history of psychosis (OR=4.3; 95% CI, 1.2-14.9), male sex (OR=4.0; 95% CI, 1.2-14.0), lower score in verbal fluency and higher score in negative symptoms (both p<0.01).
CONCLUSION: Our cross-sectional results support the hypothesis that potentially different pathways associated with the emergence of first episode psychosis may exist, including neurological premorbid alteration and environmental cannabis abuse.

Entities:  

Mesh:

Year:  2008        PMID: 18805673     DOI: 10.1016/j.schres.2008.08.001

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

2.  Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Authors:  Jasmina Mallet; Nicolas Ramoz; Yann Le Strat; Philip Gorwood; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-11       Impact factor: 5.270

3.  The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.

Authors:  Murat Yücel; Emre Bora; Dan I Lubman; Nadia Solowij; Warrick J Brewer; Sue M Cotton; Philippe Conus; Michael J Takagi; Alex Fornito; Stephen J Wood; Patrick D McGorry; Christos Pantelis
Journal:  Schizophr Bull       Date:  2010-07-25       Impact factor: 9.306

4.  The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.

Authors:  Else-Marie Løberg; Siri Helle; Merethe Nygård; Jan Øystein Berle; Rune A Kroken; Erik Johnsen
Journal:  Front Psychiatry       Date:  2014-11-18       Impact factor: 4.157

5.  Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use.

Authors:  Ahmed Mhalla; Bochra Ben Mohamed; Christoph U Correll; Badii Amamou; Anouar Mechri; Lotfi Gaha
Journal:  Ann Gen Psychiatry       Date:  2017-07-12       Impact factor: 3.455

6.  Early onset first episode psychosis: dimensional structure of symptoms, clinical subtypes and related neurodevelopmental markers.

Authors:  Maria Giuseppina Petruzzelli; Lucia Margari; Andrea Bosco; Francesco Craig; Roberto Palumbi; Francesco Margari
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-07-26       Impact factor: 4.785

7.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

8.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

9.  An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use.

Authors:  Else-Marie Løberg; Merethe Nygård; Jan Øystein Berle; Erik Johnsen; Rune A Kroken; Hugo A Jørgensen; Kenneth Hugdahl
Journal:  Front Psychiatry       Date:  2012-10-30       Impact factor: 4.157

Review 10.  Pathways from cannabis to psychosis: a review of the evidence.

Authors:  Jonathan K Burns
Journal:  Front Psychiatry       Date:  2013-10-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.